Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Common Equity: 2022-2024

Historic Common Equity for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $57.0 million.

  • Axsome Therapeutics' Common Equity fell 20.64% to $73.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.7 million, marking a year-over-year decrease of 20.64%. This contributed to the annual value of $57.0 million for FY2024, which is 70.15% down from last year.
  • Per Axsome Therapeutics' latest filing, its Common Equity stood at $57.0 million for FY2024, which was down 70.15% from $191.0 million recorded in FY2023.
  • Axsome Therapeutics' 5-year Common Equity high stood at $191.0 million for FY2023, and its period low was $57.0 million during FY2024.
  • In the last 3 years, Axsome Therapeutics' Common Equity had a median value of $109.6 million in 2022 and averaged $119.2 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Common Equity spiked by 74.32% in 2023, and later plummeted by 70.15% in 2024.
  • Axsome Therapeutics' Common Equity (Yearly) stood at $109.6 million in 2022, then spiked by 74.32% to $191.0 million in 2023, then tumbled by 70.15% to $57.0 million in 2024.